![CARDENE(R) I.V. (NICARDIPINE HYDROCHLORIDE) PREMIXED INJECTION IN 4.8% DEXTROSE 20mg IN 200mL (0.1mg/mL) 200mL BAG CARDENE(R) I.V. (NICARDIPINE HYDROCHLORIDE) PREMIXED INJECTION IN 4.8% DEXTROSE 20mg IN 200mL (0.1mg/mL) 200mL BAG](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=Highlights+2.jpg&id=461352)
CARDENE(R) I.V. (NICARDIPINE HYDROCHLORIDE) PREMIXED INJECTION IN 4.8% DEXTROSE 20mg IN 200mL (0.1mg/mL) 200mL BAG
Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction - Document - Gale OneFile: Health and Medicine
![Tratamiento con betabloqueantes en pacientes con disfunción sistólica ventricular pulmonar obstructiva crónica en medio ambulatorio Tratamiento con betabloqueantes en pacientes con disfunción sistólica ventricular pulmonar obstructiva crónica en medio ambulatorio](https://scielo.isciii.es/img/revistas/pharmacy/v7n4/205-212_04.gif)
Tratamiento con betabloqueantes en pacientes con disfunción sistólica ventricular pulmonar obstructiva crónica en medio ambulatorio
Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction - Document - Gale OneFile: Health and Medicine
![Table 5 from Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). | Semantic Scholar Table 5 from Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/756f1a156300486fff78e90803b94ee14c5b9b76/7-Table5-1.png)
Table 5 from Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). | Semantic Scholar
![Table 1 from Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. | Semantic Scholar Table 1 from Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d74cb01d7491e0648e608b1b314629930ea1a050/3-Table1-1.png)
Table 1 from Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. | Semantic Scholar
![Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta blockers Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta blockers](https://ijp-online.com/articles/2014/46/5/images/Indian%20J%20Pharmacol_2014_46_5_485_140577_t2.jpg)
Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta blockers
![Table 1 from Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. | Semantic Scholar Table 1 from Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/67c0797707e78e220989e461b8072db79ed1fb0a/5-Table1-1.png)